title: ZENECA ZD6169: a novel KATP channel opener with in vivo selectivity for urinary bladder.
abstract: (S)-N-(4-benzoylphenyl)-3,3,3-trifluoro-2-hydroxy-2-methyl-propionamide (ZD6169) is a novel ATP-sensitive potassium channel opener. Bladder activity and selectivity after oral dosing were studied in conscious, normotensive rats and dogs by monitoring cystometric and cardiovascular (CV) parameters. The reference ATP-sensitive K+ channel opener cromakalim was also evaluated in this study. ZD6169 significantly reduced micturition frequency in rats (ED50 = 0.16 mg/kg), but its effect on CV parameters was minimal (ED20 = 30 mg/kg), yielding a selectivity dose ratio of 187. The duration of action was between 7 and 24 hr at doses of 0.3 and 3 mg/kg, but it was more than 24 hr at 10 mg/kg. The ED50 value for bladder activity in dogs was less than 1.0 mg/kg, and the ED20 value for CV activity was slightly greater than 15 mg/kg but less than 20 mg/kg; the selectivity ratio was greater than 15. A significant improvement in bladder compliance was noted in dogs with ZD6169, and the bladder activity in rats was blocked by i.v. glibenclamide (3 mg/kg). Cromakalim had a bladder profile similar to that of ZD6169 but appeared to be more selective for CV parameters. In conclusion, ZENECA ZD6169 is a unique ATP-sensitive K+ channel opener with in vivo selectivity of relaxing bladder smooth muscle. This agent has the potential for treating patients with urge incontinence.
authors.affiliation: Department of Pharmacology, ZENECA Inc., Wilmington, Delaware, USA.
authors.forename: B B
authors.initials: BB
authors.lastname: Howe
authors.forename: T J
authors.initials: TJ
authors.lastname: Halterman
authors.forename: C L
authors.initials: CL
authors.lastname: Yochim
authors.forename: M L
authors.initials: ML
authors.lastname: Do
authors.forename: S J
authors.initials: SJ
authors.lastname: Pettinger
authors.forename: R B
authors.initials: RB
authors.lastname: Stow
authors.forename: C J
authors.initials: CJ
authors.lastname: Ohnmacht
authors.forename: K
authors.initials: K
authors.lastname: Russell
authors.forename: J R
authors.initials: JR
authors.lastname: Empfield
authors.forename: D A
authors.initials: DA
authors.lastname: Trainor
mesh_terms: D000255:Adenosine Triphosphate / Q000494:pharmacology*; D000577:Amides / Q000494:pharmacology*; D000818:Animals; D001577:Benzophenones / Q000494:pharmacology*; D001578:Benzopyrans / Q000494:pharmacology; D001794:Blood Pressure / Q000187:drug effects; D019806:Cromakalim; D004305:Dose-Response Relationship, Drug; D005905:Glyburide / Q000494:pharmacology; D006339:Heart Rate / Q000187:drug effects; D008297:Male; D015221:Potassium Channels / Q000187:drug effects*; D011758:Pyrroles / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D001743:Urinary Bladder / Q000187:drug effects*
chemical_list: D000577:Amides; D001577:Benzophenones; D001578:Benzopyrans; D015221:Potassium Channels; D011758:Pyrroles; C095007:Zeneca ZD 6169; D019806:Cromakalim; D000255:Adenosine Triphosphate; D005905:Glyburide